AnaptysBio (ANAB) Tests The Royalty Story On Questions Over Whether Shares Are Fully Valued
AnaptysBio (ANAB) has drawn fresh attention after recent trading left the stock down about 8% over the past month and roughly 6% over the past 3 months, despite strong longer term returns.
Recent trading weakness has taken some heat out of the rally, with AnaptysBio’s share price down 2.34% on the day and 7.87% over the past month. Even so, the year to date share price return of 19.84% sits alongside a very large 1 year total shareholder return of about 300.88%.
Spot shifts in momentum around AnaptysBio by comparing it with other fast moving biotech and healthcare names screened from our 15 high quality undiscovered gems.
Bulls point to AnaptysBio’s recent share price gains and clinical pipeline, while bears highlight the latest share price weakness and ongoing losses. Which side does the current valuation appear to support?
Most Popular Narrative: 40.1% Undervalued
AnaptysBio’s most followed narrative pegs fair value at $90 a share, well above the recent close near $53.87. This suggests a wide gap between the narrative and the current price.
ANAB has a scaling and rising royalty stream, one up and coming new royalty, a loan that dies in 2027 which will result in a doubling of revenue, and a lawsuit that could soon double the value of the stock.
See why 3 investors see AnaptysBio as 40% undervalued.
Result: Fair Value of $90 (UNDERVALUED)
Still, the AnaptysBio story leans heavily on ongoing royalty flows and a favorable lawsuit outcome, so any setback on Jemperli or in court could quickly undercut that positive case.
Find out about the key risks to this AnaptysBio narrative.
Another View: AnaptysBio Looks Expensive On Sales
The first narrative leans on royalties and a $90 fair value, yet a simple P/S check tells a different story. AnaptysBio trades on a P/S of 6.9x while the fair ratio sits at 4.5x. That gap implies investors are already paying up on today’s revenue base.
Compared with the US Biotechs industry average P/S of 12.3x and a peer group at 7.3x, the stock is cheaper than some rivals but still well above that fair ratio anchor. For anyone weighing the royalty story against this richer sales multiple, consider which signal feels more important to your thesis.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
This article so far presents mixed messages on AnaptysBio. If you want to move quickly and form your own view, begin by reviewing the 2 key rewards
Looking for more AnaptysBio sized ideas?
Do not stop at AnaptysBio. Broaden your watchlist now with fresh ideas sourced from data driven screeners that surface opportunities you might otherwise overlook.
- Target value upside by scanning a curated set of companies trading below intrinsic worth through the 32 high quality undervalued stocks.
- Prioritise resilience by focusing on businesses with strong finances using the list of solid balance sheet and fundamentals (23 results).
- Dial down portfolio risk by filtering for companies with steadier profiles through the 11 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com